In the early weeks of the COVID-19 public health crisis, the federal government prioritized a swift response to the economic impact of the novel coronavirus, including several pieces of legislation that sought to infuse cash into vulnerable businesses—including millions of small businesses.
More than ever before, banks are relying on third-party vendors for important services such as marketing, underwriting assistance, technology, collections, settlement services and even outsourcing of product lines.
Founder’s stock refers to the equity granted, typically in the form of common stock, to founders of a company for their preformation efforts in building the company.
Founders must contend with many important decisions early in the life of a startup, including selecting the appropriate corporate structure.
The Federal Trade Commission (FTC) has requested comments on its proposed Made in USA rule, which would codify its Enforcement Policy Statement on U.S. Origin Claims and allow the FTC to seek civil penalties for violations.
The Federal Trade Commission (FTC) has sued a California-based company named Golden Sunrise Nutraceutical, Inc., and some of its officers, alleging that the company is falsely marketing its Emergency D-Virus plan as a treatment for COVID-19.
The Federal Trade Commission (FTC) has filed suit against three online marketers for failing to deliver on promises that they could quickly ship products like face masks, hand sanitizer and other personal protective equipment related to the coronavirus pandemic.
In addition to the Federal Trade Commission, the National Advertising Division (NAD) has also been active with cases regarding COVID-19 claims.
A panel of the National Advertising Review Board (NARB) recommended that S.C. Johnson & Son, Inc., discontinue the unqualified “non-toxic” claim on package labeling for its Windex Vinegar Glass and Window Cleaner.
Over the past five months, Congress and the Centers for Medicare & Medicaid Services (CMS) have dramatically, but temporarily, expanded coverage and reimbursement for telehealth services in response to the COVID-19 pandemic.